Phase 3 Head and Neck Cancer Trial, Recruiting NCT06737822 Sponsor: All India Institute of Medical Sciences, Jodhpur Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT06737822
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with oral squamous cell cancer (a type of mouth cancer) and have not yet received any treatment, confirmed by a tissue or cell sample test
  • People whose cancer has been staged as a certain level of local and regional spread (clinical Stage cT1–4a, cN2–N3, M0 under the 2018 UICC staging system) — confirm exact staging details with the trial site
  • People who have no signs of cancer that has spread to distant parts of the body, as shown by chest imaging
  • People with a general health and activity level rated as ECOG 0–2, meaning they are able to carry out at least some daily activities (confirm with trial site)
  • People who have no medical reasons preventing them from receiving the chemotherapy drug Cisplatin or radiation therapy
  • People whose case has been reviewed by a specialist multidisciplinary team and considered suitable for treatment aimed at curing the cancer
  • People whose blood, liver, and kidney function results meet the minimum levels required for safe participation (confirm specific values with trial site)

Who may not be able to join:

  • People who are pregnant
  • People who have a history of moderate to severe hearing loss
  • People who have had a previous cancer diagnosis, other than certain skin cancers (non-melanoma) or a very early-stage cervical condition called carcinoma in situ
  • People who have lost more than 15% of their body weight in the past 6 months
  • People with a known diagnosis of HIV, hepatitis B, or hepatitis C

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dharma R Poonia, MS DNB, AIIMS Jodhpur

Phone: 9958654196

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
All India Institute of Medical Sciences, Jodhpur
Registry
ClinicalTrials.gov
Start date
20 December 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Disease Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov